Have a feature idea you'd love to see implemented?
Let us know!
NXTC NextCure Inc
Price (delayed)
$1.27
Market cap
$35.53M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.19
Enterprise value
$20.27M
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through its proprietary FIND-IO™ platform, NextCure studies various immune
Highlights
NXTC's net income is up by 13% year-on-year and by 3.9% since the previous quarter
The EPS has grown by 13% YoY and by 3.9% from the previous quarter
The quick ratio has plunged by 52% YoY and by 20% from the previous quarter
NextCure's equity has decreased by 38% YoY and by 14% QoQ
Key stats
What are the main financial stats of NXTC
Market
Valuations
Earnings
Shares outstanding
27.98M
Market cap
$35.53M
Enterprise value
$20.27M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.42
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$61.28M
EBITDA
-$57.44M
Free cash flow
-$46.46M
Per share
Balance sheet
Liquidity
EPS
-$2.19
Free cash flow per share
-$1.66
Book value per share
$3.05
Revenue per share
$0
TBVPS
$3.67
Total assets
$102.59M
Total liabilities
$17.15M
Debt
$5.59M
Equity
$85.44M
Working capital
$79.62M
Debt to equity
0.07
Current ratio
8.35
Quick ratio
7.98
Net debt/EBITDA
0.27
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-50.5%
Return on equity
-57.6%
Return on invested capital
-60.7%
Return on capital employed
-66.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NXTC stock price
How has the NextCure stock price performed over time
Intraday
-7.97%
1 week
-4.51%
1 month
-8.63%
1 year
-3.05%
YTD
11.4%
QTD
-7.3%
Financial performance
How have NextCure's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$66.21M
Net income
-$61.28M
Gross margin
N/A
Net margin
N/A
NXTC's net income is up by 13% year-on-year and by 3.9% since the previous quarter
NextCure's operating income has increased by 10% YoY and by 3.9% from the previous quarter
Growth
What is NextCure's growth rate over time
Valuation
What is NextCure stock price valuation
P/E
N/A
P/B
0.42
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 13% YoY and by 3.9% from the previous quarter
The P/B is 55% lower than the 5-year quarterly average of 1.0 but 13% higher than the last 4 quarters average of 0.4
NextCure's equity has decreased by 38% YoY and by 14% QoQ
Efficiency
How efficient is NextCure business performance
NXTC's return on equity is down by 32% year-on-year and by 8% since the previous quarter
NXTC's ROA is down by 25% YoY and by 6% QoQ
NextCure's return on invested capital has decreased by 25% YoY and by 9% QoQ
Dividends
What is NXTC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NXTC.
Financial health
How did NextCure financials performed over time
NXTC's current ratio has dropped by 52% year-on-year and by 22% since the previous quarter
The quick ratio has plunged by 52% YoY and by 20% from the previous quarter
NXTC's debt is 93% smaller than its equity
The debt to equity is up by 40% year-on-year and by 17% since the previous quarter
NextCure's equity has decreased by 38% YoY and by 14% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.